240 related articles for article (PubMed ID: 35954308)
1. Efp/TRIM25 and Its Related Protein, TRIM47, in Hormone-Dependent Cancers.
Azuma K; Inoue S
Cells; 2022 Aug; 11(15):. PubMed ID: 35954308
[TBL] [Abstract][Full Text] [Related]
2. TRIM47 activates NF-κB signaling via PKC-ε/PKD3 stabilization and contributes to endocrine therapy resistance in breast cancer.
Azuma K; Ikeda K; Suzuki T; Aogi K; Horie-Inoue K; Inoue S
Proc Natl Acad Sci U S A; 2021 Aug; 118(35):. PubMed ID: 34433666
[TBL] [Abstract][Full Text] [Related]
3. TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with G3BP2 in prostate cancer.
Takayama KI; Suzuki T; Tanaka T; Fujimura T; Takahashi S; Urano T; Ikeda K; Inoue S
Oncogene; 2018 Apr; 37(16):2165-2180. PubMed ID: 29379164
[TBL] [Abstract][Full Text] [Related]
4. Transcriptomic analysis of hormone-sensitive patient-derived endometrial cancer spheroid culture defines Efp as a proliferation modulator.
Yang C; Ikeda K; Horie-Inoue K; Sato W; Hasegawa K; Takeda S; Itakura A; Inoue S
Biochem Biophys Res Commun; 2021 Apr; 548():204-210. PubMed ID: 33647797
[TBL] [Abstract][Full Text] [Related]
5. Combined Use of Immunoreactivities of RIG-I with Efp/TRIM25 for Predicting Prognosis of Patients With Estrogen Receptor-positive Breast Cancer.
Sato J; Azuma K; Kinowaki K; Ikeda K; Ogura T; Takazawa Y; Kawabata H; Kitagawa M; Inoue S
Clin Breast Cancer; 2021 Oct; 21(5):399-407.e2. PubMed ID: 33386231
[TBL] [Abstract][Full Text] [Related]
6. Efp promotes in vitro and in vivo growth of endometrial cancer cells along with the activation of nuclear factor-κB signaling.
Sato W; Ikeda K; Urano T; Abe Y; Nakasato N; Horie-Inoue K; Takeda S; Inoue S
PLoS One; 2018; 13(12):e0208351. PubMed ID: 30586414
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of TRIM47 inhibits breast cancer tumorigenesis and progression through the inactivation of PI3K/Akt pathway.
Wang Y; Liu C; Xie Z; Lu H
Chem Biol Interact; 2020 Feb; 317():108960. PubMed ID: 31981573
[TBL] [Abstract][Full Text] [Related]
8. Increased Expression of Tripartite Motif (TRIM) 47 Is a Negative Prognostic Predictor in Human Prostate Cancer.
Fujimura T; Inoue S; Urano T; Takayama K; Yamada Y; Ikeda K; Obinata D; Ashikari D; Takahashi S; Homma Y
Clin Genitourin Cancer; 2016 Aug; 14(4):298-303. PubMed ID: 26873435
[TBL] [Abstract][Full Text] [Related]
9. Oestrogen causes degradation of KLF5 by inducing the E3 ubiquitin ligase EFP in ER-positive breast cancer cells.
Zhao KW; Sikriwal D; Dong X; Guo P; Sun X; Dong JT
Biochem J; 2011 Jul; 437(2):323-33. PubMed ID: 21542805
[TBL] [Abstract][Full Text] [Related]
10. An Integrated Systems Biology Approach Identifies TRIM25 as a Key Determinant of Breast Cancer Metastasis.
Walsh LA; Alvarez MJ; Sabio EY; Reyngold M; Makarov V; Mukherjee S; Lee KW; Desrichard A; Turcan Ş; Dalin MG; Rajasekhar VK; Chen S; Vahdat LT; Califano A; Chan TA
Cell Rep; 2017 Aug; 20(7):1623-1640. PubMed ID: 28813674
[TBL] [Abstract][Full Text] [Related]
11. The ubiquitin ligase TRIM25 targets ERG for degradation in prostate cancer.
Wang S; Kollipara RK; Humphries CG; Ma SH; Hutchinson R; Li R; Siddiqui J; Tomlins SA; Raj GV; Kittler R
Oncotarget; 2016 Oct; 7(40):64921-64931. PubMed ID: 27626314
[TBL] [Abstract][Full Text] [Related]
12. TRIM47 is up-regulated in colorectal cancer, promoting ubiquitination and degradation of SMAD4.
Liang Q; Tang C; Tang M; Zhang Q; Gao Y; Ge Z
J Exp Clin Cancer Res; 2019 Apr; 38(1):159. PubMed ID: 30979374
[TBL] [Abstract][Full Text] [Related]
13. Estrogen-responsive finger protein as a new potential biomarker for breast cancer.
Suzuki T; Urano T; Tsukui T; Horie-Inoue K; Moriya T; Ishida T; Muramatsu M; Ouchi Y; Sasano H; Inoue S
Clin Cancer Res; 2005 Sep; 11(17):6148-54. PubMed ID: 16144914
[TBL] [Abstract][Full Text] [Related]
14. RNA-binding activity of TRIM25 is mediated by its PRY/SPRY domain and is required for ubiquitination.
Choudhury NR; Heikel G; Trubitsyna M; Kubik P; Nowak JS; Webb S; Granneman S; Spanos C; Rappsilber J; Castello A; Michlewski G
BMC Biol; 2017 Nov; 15(1):105. PubMed ID: 29117863
[TBL] [Abstract][Full Text] [Related]
15. Efp as a primary estrogen-responsive gene in human breast cancer.
Ikeda K; Orimo A; Higashi Y; Muramatsu M; Inoue S
FEBS Lett; 2000 Apr; 472(1):9-13. PubMed ID: 10781795
[TBL] [Abstract][Full Text] [Related]
16. All Paths Lead to TRIM25.
Zhou H; Costello JC
Trends Cancer; 2017 Oct; 3(10):673-675. PubMed ID: 28958384
[TBL] [Abstract][Full Text] [Related]
17. Structural analysis of RIG-I-like receptors reveals ancient rules of engagement between diverse RNA helicases and TRIM ubiquitin ligases.
Kato K; Ahmad S; Zhu Z; Young JM; Mu X; Park S; Malik HS; Hur S
Mol Cell; 2021 Feb; 81(3):599-613.e8. PubMed ID: 33373584
[TBL] [Abstract][Full Text] [Related]
18. Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth.
Urano T; Saito T; Tsukui T; Fujita M; Hosoi T; Muramatsu M; Ouchi Y; Inoue S
Nature; 2002 Jun; 417(6891):871-5. PubMed ID: 12075357
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic and proteolytic inactivation of 14-3-3sigma in breast and prostate cancers.
Horie-Inoue K; Inoue S
Semin Cancer Biol; 2006 Jun; 16(3):235-9. PubMed ID: 16682214
[TBL] [Abstract][Full Text] [Related]
20. Analysis of estrogen-responsive finger protein expression in benign and malignant human breast.
Thomson SD; Ali S; Pickles L; Taylor J; Pace PE; Lymboura M; Shousha S; Coombes RC
Int J Cancer; 2001 Jan; 91(2):152-8. PubMed ID: 11146438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
